Shrink Nanotechnologies, Inc. (“Shrink”) (OTCBB:INKN – News), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today the formation a new wholly-owned subsidiary, Shrink Chips LLC, which is dedicated to the commercialization of a suite of next-generation biotechnology research tools, including its patent-pending ShrinkChip Rapid Prototyping System (RPS) which is used to inexpensively and flexibly manufacture microfluidic chips, or Lab-on-a-Chip (LOC), devices as well as many other biological and chemical sensors.
LOC devices are commonly used to screen new drugs for toxicity levels, and develop new vaccines, therapeutics and novel drug therapies for some of the world’s most prevalent and challenging diseases, including cancer, diabetes, Parkinson’s and Alzheimer’s. The use of and analysis from LOC devices, especially in the case of prototyping devices, represents a high cost for R&D groups with academic and commercial organizations. Shrink believes that companies who use Shrink’s RPS solutions for initial testing, prototyping and small scale production designs will benefit from increased design flexibility with significant cost reduction.
ShrinkChips’s initial suite of products will address two arget markets:

• a desktop-sized rapid prototyping platform for use in government laboratories, academic research facilities and commercial organizations in the U.S. and abroad; and
• an “out-of-the-box” complete biotechnology test kit for use in high school biology labs through post graduate studies.
Shrink believes that the markets for the ShrinkChip RPS prototyping platform, which is “open” source, will increase over time as the system is deployed, and academic researchers begin to publish results based on work done using the system and as Shrink begins to go to market with products it has designed and commercialized using the platform.
Mark L. Baum, CEO of Shrink Nanotechnologies, Inc. said, “Since our scientific founder, Dr. Michelle Khine, began to receive attention for her novel method of creating low cost microfluidic, biosensing and chemical sensing devices, Shrink has accumulated interest for a commercial system based on Dr. Khine’s ideas. Now that we are getting closer and closer to bringing Dr. Khine’s ideas to the market, we have formed ShrinkChips and will have a focused team working on this project, with a specific mission and the resources to pursue the commercial development of the ShrinkChip Rapid Prototyping System, ultimately accelerating the time-to-market for several new bioscience products.”
See also:
Shrink Solar
Shrink Nano Products
Shrink Nano Diagnostic Products
Shrink Nano Technologies
Shrink Nano TR35 Award

{ Comments on this entry are closed }

CellAlign’s key feature is a micro-fabricated substrate with non-periodic (or random) linear patterned grooves that allow for the alignment of cells along a single axis. The unique design is ideal for growing biological tissues from stem cells, especially those that naturally grow in a linear fashion such as in cardiac and nerve tissues.

“CellAlign has the potential to grow sheets of living tissues that may one day act as ‘band-aids’ to patch and repair, and possibly regenerate, damaged or diseased organs,” said Mark L. Baum, president of Shrink Nanotechnologies, Inc. “Clinical practices and medical specialties are increasingly turning to cellular-based therapies to solve some of the world’s most perplexing health maladies. As our intellectual property position improved with CellAlign, future licensing potential represents a significant market opportunity for Shrink.”

In the United States, tissue engineering and cell therapy comprised a $6.9 billion market for regenerative products in 2009, and is expected to approach $32 Billion by 2018, according to the 2010 MedMarket Diligence’s Report, “Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018.” The report says the market for cellular therapies may benefit many disorders, including degenerative and traumatic orthopedic and spine injuries, cardiac and vascular disease, neurological disorders, diabetes, inflammatory diseases, and tooth decay.

{ Comments on this entry are closed }

Shrink Nanotechnologies Enters into Technology Integration and Development Agreement With Lydall Solutech BV for Solupor® Membrane

June 28, 2010

Under the terms of the agreement, Lydall Solutech, a Lydall, Inc. (NYSE: LDL) company, will provide Shrink with certain quantities of its Solupor® membrane for the purpose of conducting a one-year research and development project. The goal of the project is to develop a robust, ultra-rapid diagnostic platform that increases the sensitivity of fluorescent-based assays [...]

Read the full article →

Emerging Stock Report Initiates Independent Research Coverage on Shrink Nanotechnologies, Inc.

May 24, 2010

CALGARY, Alberta, May 24, 2010 (GLOBE NEWSWIRE) — Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on Shrink Nanotechnologies, Inc. (Pink Sheets:INKN – News). Emerging Stock Report is currently offering a complimentary trial subscription to the investment community. To view the Report in its entirety visit: EmergingStockReport To [...]

Read the full article →

Shrink Nanotechnologies’ Biotech R&D Group Files Patent on Rapid Prototyping System for the $2.6 Billion Biochip Market

May 24, 2010

CARLSBAD, Calif.–(BUSINESS WIRE)–Shrink Nanotechnologies, Inc. (“Shrink”), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications related to its rapid prototyping system for the manufacture of microfluidic chips, or Lab-on-a-Chip (LOC) devices, have been filed. [...]

Read the full article →

Shrink Nanotechnologies’ Biotech R&D Group Files Key Patent on StemDisc Biomedical Research Tool

May 21, 2010

CARLSBAD, Calif.–(BUSINESS WIRE)–Shrink Nanotechnologies, Inc. (“Shrink”), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications for its stem cell research and drug discovery tool StemDisc™ have been filed. StemDisc is Shrink’s latest bioscience application [...]

Read the full article →

CORRECTING and REPLACING Shrink Solar’s Quantum Dot Technology Achieves 12.6% Optical Efficiency in Published Study

May 17, 2010

Findings Published in ‘Applied Physics Letters’ Show Shrink’s Quantum Dot Technology Generates Nearly Twice the Photocurrent in Silicon Cells as Compared to Leading Photovoltaic Materials Shrink Nanotechnologies, Inc. (“Shrink”), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors and biotechnology research and development tools businesses, is [...]

Read the full article →

Shrink Nanotechnologies Resumes Trading under Symbol INKN

May 12, 2010

CARLSBAD, Calif.–(BUSINESS WIRE)–Shrink Nanotechnologies, Inc. (“Shrink”), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that the “D” in its ticker symbol has been removed, and the Company has resumed trading under “INKN,” effective at the open [...]

Read the full article →

Shrink Solar LLC Unveils 5th Generation Solar Concentrator Technology in Prototype Device

May 10, 2010

CARLSBAD, Calif.–(BUSINESS WIRE)–Shrink Nanotechnologies, Inc. (“Shrink”), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that its wholly-owned subsidiary, Shrink Solar LLC, is pleased to unveil the fifth generation of its solar concentrator technology, which is based [...]

Read the full article →

Shrink Nanotechnologies Executes 3-Year Sponsored Research Agreement with Leading Science and Engineering Public University in California

May 6, 2010

CARLSBAD, Calif.–(BUSINESS WIRE)–Shrink Nanotechnologies, Inc. (“Shrink”), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that it has entered into a three-year sponsored research agreement with a leading science and engineering campus within the largest public university [...]

Read the full article →